<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294982</url>
  </required_header>
  <id_info>
    <org_study_id>20100011031</org_study_id>
    <nct_id>NCT01294982</nct_id>
  </id_info>
  <brief_title>Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency</brief_title>
  <official_title>Phase II, Randomized, Double-blind, Placebo-controlled Trial of the AOBO-001 for the Treatment of Overactive Bladder With Symptoms of Urge Urinary Incontinence and Frequency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Oriental Bioengineering, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Oriental Bioengineering, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the
      study product, AOBO-001, when taken by adults with symptoms of overactive bladder. AOBO-001,
      is experimental, which means that the U. S. Food and Drug Administration (FDA) has not yet
      approved it for use. AOBO-001 has been approved in China as a prescription drug product to
      treat bedwetting in children. AOBO-001 is also approved in Hong Kong as a dietary supplement
      to improve quality of life for people with urinary incontinence. AOBO-001 is a botanical
      (from a plant) product. It is prepared from the seeds of Xanthoceras sorbifolia bunge plant,
      which is a flowering tree grown in Northern China. Approximately 60 subjects who are 18 years
      of age and older are expected to participate in this study at up to 8 investigational sites.
      Each subject will complete 6 visits to the study site over a 14-week period. Subjects will
      consume 8 capsules of the assigned test product twice daily (that is, 16 capsules daily).
      Capsules will be taken with at least 6 ounces of water approximately 30 minutes before
      breakfast and 30 minutes before dinner. If a subject qualifies, he/she will be randomly (by
      chance) assigned to one of three study treatment groups. Subjects in one group will consume
      capsules containing a daily dose of 3.2 grams of AOBO-001; a second group will consume
      capsules containing a daily dose of 6.4 grams of AOBO-001; and a third group will consume
      capsules containing a placebo (no active ingredients). Subjects will have a 2 in 3 chance of
      being assigned to an active study treatment group. Neither the subject nor the study doctor
      will know to which study treatment group the subject has been assigned, but this information
      is available in case of a medical emergency. There will be a time during the study dosing
      schedule when all subjects will consume capsules containing a placebo (no active
      ingredients). Subjects will not be told when they are receiving the placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo-controlled Phase 2 clinical trial will evaluate the
      safety and efficacy of AOBO-001 in adults with overactive bladder. The primary objective of
      this study is to evaluate the efficacy of AOBO 001 compared with placebo on the basis of the
      change from baseline in average number of micturition episodes per 24 hours from the 3-day
      diaries and average number of urge urinary incontinence episodes per 24 hours from the 3 day
      diaries during the double-blind treatment period in adult patients with OAB. Secondary
      efficacy objectives are to evaluate the efficacy of AOBO-001 compared with placebo on the
      basis of the number and severity of urgency episodes by using the Patient's Perception of
      Intensity of Urgency Scale (PPIUS), nocturia episodes, volume voided per micturition, and
      Patient Perception of Bladder Condition (PPBC) global assessment measure. An additional
      secondary objective is to evaluate the safety and tolerability of AOBO-001 compared with
      placebo.

      Eligible patients will be randomized in equal proportions to double-blind treatment with AOBO
      001 1.6 g twice daily (3.2 g daily), AOBO-001 3.2 g twice daily (6.4 g daily) or placebo
      capsules twice daily.

      Efficacy assessments include urinary diary assessments, including the number of micturitions
      (daytime, nighttime), number of urge incontinence episodes, number/grading of urgency
      episodes (Patient's Perception of Intensity of Urgency Scale or PPIUS), and volume of voided
      urine; and Patient Perception of Bladder Condition (PPBC) questionnaire. Safety assessments
      include post-void residual urine volume measured by bladder scan; vital signs, 12-lead ECGs,
      complete or brief physical examinations, clinical laboratory safety tests, and
      treatment-emergent adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average number of micturitions per 24 hours from 3-day urinary diaries compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Change in the average number of micturitions per 24 hours from the 3-day diaries from baseline to endpoint of the 12 week double-blind treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in average number of urge incontinence episodes per 24 hours from 3-day urinary diaries compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Change in average number of urge urinary incontinence episodes per 24 hours from the 3-day diaries from baseline to endpoint of the 12 week double-blind treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in volume voided per micturition compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Volume voided per micturition over 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intensity of urgency episodes compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Intensity of urgency episodes, PPIUS grade 3+4, intensity of urgency episodes, PPIUS grades 0-4, and maximum urgency intensity at void episodes (PPIUS grades 0-4) per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daytime and sleeptime micturitions compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Number of daytime and sleeptime (nocturia) micturition episodes per 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly urge incontinence episodes compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Number of urge urinary incontinence episodes per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PPBC score compared to baseline</measure>
    <time_frame>Endpoint (up to 12 weeks of double-blind treatment)</time_frame>
    <description>Patient Perception of Bladder Condition (PPBC) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>During double-blind treatment phase</time_frame>
    <description>Treatment-emergent adverse events including subject reporting, clinical observations, and clinically significant abnormal findings as measured by bladder scan, vital signs, 12-lead ECGs, complete or brief physical examinations and clinical laboratory safety tests.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>1.6 g AOBO-001 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOBO-001 400 mg Oral Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.2 g AOBO-001 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOBO-001 400 mg Oral Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AOBO-001</intervention_name>
    <description>AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily</description>
    <arm_group_label>1.6 g AOBO-001 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AOBO-001</intervention_name>
    <description>AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily</description>
    <arm_group_label>3.2 g AOBO-001 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Oral Capsules twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is male or female aged 18 years or older and provides written informed
             consent;

          2. Patient has had symptoms of OAB, including urinary frequency, urgency or urge
             incontinence, for at least 3 months prior to the screening visit;

          3. Patient is compliant with completing 3 consecutive days of the urinary diary each week
             and at least 85% compliant with taking placebo capsules during the 2-week placebo
             run-in period;

          4. Patient experiences an average micturition frequency of â‰¥8 times per a 24-hour period
             based on the 24-hour average of 3 consecutive days of urinary diary data during the
             last week of the 2-week placebo run-in period;

          5. Patient has had at least 4 episodes of incontinence over a 3 consecutive day urinary
             diary period during the 2-week placebo run-in period; and

          6. Patient has had at least 4 episodes of urgency (PPIUS Grade 3 or 4) with or without
             incontinence over a 3 consecutive day urinary diary period during the 2-week placebo
             run-in period.

        Exclusion Criteria:

          1. Patients with known allergy to plants of Sapindaceae family, including maple syrup,
             litchi (Litchi chinensis), rambutan (Nephelium lappaceum), longan (Euphoria longana),
             ackee (Blighia sapida) and Spanish Lemon (Melicoccus bijugus).

          2. Pregnant women or women who intend to become pregnant during the study or women of
             childbearing potential who are sexually active and practicing an unreliable method of
             birth control or will be lactating during the study. Reliable contraceptive methods
             are intra-uterine devices, double-barrier method (condom with spermicide),
             contraceptive pills of combination type, hormonal implants and injectable or patch
             contraceptives;

          3. Clinically significant outflow obstruction (at the discretion of the investigator);

          4. Significant stress incontinence or mixed stress/urge incontinence where stress is the
             predominant factor, as determined by the investigator;

          5. Patient with indwelling catheters or practicing intermittent self-catheterization;

          6. Evidence of a symptomatic urinary tract infection, chronic inflammation such as
             interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous
             or current malignant disease of the pelvic organs;

          7. Non-drug OAB treatment such as bladder-training, biofeedback and pelvic floor
             exercises are permissible if established at least 4 weeks prior to study start and
             intended to be continued throughout the study; electrostimulation therapy is not
             permissible at any time;

          8. Use of drugs intended to treat urinary incontinence, such as darifenacin (Enablex),
             fesoterodine (Toviaz), oxybutynin (Ditropan, Ditropan XL, Oxytrol), solifenacin
             (Vesicare), tolterodine (Detrol, Detrol LA), and trospium (Sanctura, Sanctura XR);

          9. Any clinically significant condition, which in the opinion of the investigator makes
             the patient unsuitable for the trial, including without limitation, major
             cardiovascular or cerebrovascular event (e.g., myocardial infarction, stroke, unstable
             angina, transient ischemic attacks) within the past year, major neurological disorders
             (e.g., paralysis or neuropathies, multiple sclerosis), major psychiatric diseases
             (e.g., major depression, generalized anxiety, psychosis), unstable or poorly
             controlled chronic diseases (e.g., uncontrolled moderate to severe hypertension or
             poorly controlled diabetes mellitus), and moderate to severe renal or hepatic disease;

         10. Participation in any clinical trial within 30 days prior to randomization;

         11. Women who suffer from undiagnosed vaginal bleeding;

         12. Employees of AOBO, third parties associated with the study, or the study site; and

         13. Patient who did not complete the urinary diary (3 consecutive days of valid urinary
             diary data each week) and did not take placebo run-in study medication (at least 85%
             compliance) according to the instructions during the placebo run-in period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Du, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>American Oriental Bioengineering, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associate, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myron I. Murdock M.D. LLC</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OAB</keyword>
  <keyword>Over Active Bladder</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>Urinary Urge Incontinence</keyword>
  <keyword>Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

